Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PD-L1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PD-L1 (CD274) ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View PD-L1 Products |
| Gene Delivery | PD-L1 (CD274) Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Cell-based assays preserve native conformation. |
View PD-L1 Products |
| Benchmark Ab | Anti-PD-L1 (Sequence of Atezolizumab / Durvalumab) Recombinant positive control. Sequence Verified. |
View PD-L1 Products |
| Validator | PD-L1 (CD274) siRNA Set For knockdown verification and specificity control. |
View PD-L1 Products |
| Cross-Species Panel | Human/Mouse/Cynomolgus PD-L1 ECD-Fc For preclinical toxicology and epitope conservation analysis. >95% purity, Sequence Verified. |
View PD-L1 Products |
| Counter-Screen | PD-L2 (CD273) ECD-Fc Protein For selectivity assays vs highly homologous family member. |
View PD-L2 Products |
| Pathway Partner | PD-1 (CD279) Direct binding partner; essential for competitive blocking assays and mechanism-of-action studies. |
View PD-1 Products |
| Combination Target A | TIGIT Synergistic immune checkpoint often targeted in bispecific or combination therapies. |
View TIGIT Products |
| Combination Target B | LAG-3 Key parallel pathway implicated in PD-1/PD-L1 blockade resistance. |
View LAG-3 Products |
| Combination Target C | CTLA-4 Synergistic checkpoint target for bispecific development. |
View CTLA-4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Translation (Cyno/Mouse) | Human/Mouse/Cyno ortholog proteins available with >95% purity, Sequence Verified. |
| Subfamily Counter Screening (PD-L2 Selectivity) | Homolog panel proteins (PD-L2) strictly verified by mass spec; Endotoxin Controlled. |
| Internalization Efficiency (ADC Development) | Lentivirus for Stable Cell Line generation preserving native conformation; ECD-Fc for binding kinetics. |
| Glycosylation-Dependent Binding Variations | Strictly HEK293 Expressed preserving native post-translational modifications. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Atezolizumab, Durvalumab biosimilars) included with Endotoxin Controlled specifications. |
| Off-Target False Positives | Validated siRNA included for specificity checks and background signal elimination. |
Live PD-L1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PD-L1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to next-generation modalities including Bispecific Antibodies, ADCs, and small molecule degraders. As first-generation therapies (like Atezolizumab and Durvalumab) establish baseline clinical utility across multiple solid tumors, the next wave of R&D targets resistance mechanisms (e.g., JAK/STAT pathway alterations, antigen presentation defects), microenvironment modulation, and conditional activation strategies. Integration of PD-L1 with orthogonal immune modulators (TGF-beta, 4-1BB, CD47, TIGIT, LAG-3) represents a critical future trend requiring rigorous heterodimer validation and precise epitope mapping. Small molecule oral inhibitors and PROTACs are emerging for refractory tumors where antibody penetration is limited. Subcutaneous formulation development is also becoming a key differentiation factor for patient compliance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAbs) | Roche, AstraZeneca, Merck KGaA | NSCLC, Urothelial Carcinoma, HCC | Fc-effector characterization & Affinity Ranking (Need high-purity ECD-Fc proteins and silenced/wild-type Fc controls) |
| Bispecific Antibody | Merck (M7824), MacroGenics, Alphamab, BioNTech | Refractory Solid Tumors, NSCLC, Gastric Cancer | Heterodimer Validation & Epitope Binning (Need cross-reactive Abs, dual-antigen panels, and Target orthologs) |
| Antibody-Drug Conjugates (ADC) | Daiichi Sankyo, Seagen, Pipeline biotechs | PD-L1+ Advanced Solid Tumors | Internalization Assay (Need high-purity ECD-Fc for binding, Lentivirus for cell-based uptake) |
| Small Molecules & Degraders | Incyte, Polaris, Aurigene | Oral Checkpoint Inhibition, Refractory Tumors | Selectivity Assay (Need High-Purity WT and Mutant Proteins; PD-L1 vs PD-L2 for off-target screening) |
PD-L1 Functional Domains & Target Identity
PD-L1 (CD274) is a type I transmembrane protein containing two immunoglobulin-like domains: an Ig-like V-type domain (critical for PD-1 binding) and an Ig-like C2-type domain (membrane proximal). These domains form the extracellular region used in ECD-Fc reagents. The target is resolved as CD274 (UniProt Q9NZQ7). Loosely identical alias PD-L1 should be used interchangeably. High-purity domain-specific proteins enable precise epitope mapping and selectivity assays.